Janssen Sciences Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that clinical data for simeprevir, its hepatitis C virus treatment, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver in Vienna, from April 22 to 26.
Simeprevir is a NS3/4A protease inhibitor and a number of presentations on its efficacy will be reported at the conference. Early-stage data on the investigational nucleotide analog polymerase inhibitors AL-335 and AL-516 will also be presented.
"Janssen has an extensive and ongoing clinical trial programm for hepatitis C, including confirmatory and new exploratory studies, and we look forward to sharing these results," said Gaston Picchio, hepatitis disease area leader, Janssen.